Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT3 | Q9Y243 | 6/20 | 0.40 |
| ▸ | AKT2 | P31751 | 5/20 | 0.40 |
| ▸ | AKT1 | P31749 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680729 | 0.95 | GAA (0.43) | AKT3AKT2AKT1GAAHPGD | |
| SCHEMBL14267027 | 0.90 | BRD4 (0.43) | AKT3AKT2AKT1GAAHPGD | |
| SCHEMBL680938 | 0.90 | BRD4 (0.43) | AKT3AKT2AKT1GAAHPGD | |
| SCHEMBL681002 | 0.88 | AKT3 (0.47) | AKT3AKT2AKT1GAAHPGD | |
| SCHEMBL16261013 | 0.88 | GAA (0.40) | AKT3AKT2AKT1GAAHPGD | |
| SCHEMBL680144 | 0.86 | AKT3 (0.50) | AKT3AKT2AKT1GAAHPGD | |
| SCHEMBL680741 | 0.86 | SLC6A2 (0.40) | AKT3AKT2AKT1GAAHPGD | |
| SCHEMBL679641 | 0.86 | AKT3 (0.49) | AKT3AKT2AKT1GAAHPGD | |
| SCHEMBL680817 | 0.85 | AKT3 (0.39) | AKT3AKT2AKT1GAAHPGD | |
| SCHEMBL681206 | 0.83 | OPRL1 (0.44) | AKT3AKT2AKT1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8003651-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | GENENTECH, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | PIK3CA, DPYD, CDK2 | AKT3 27/4885AKT2 23/4885AKT1 33/4885 |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | AKT3 4/4885AKT2 2/4885AKT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.